Responsive Image

 

 

Responsive Image

Neuroinmunología

Líneas de investigación

Investigación sobre la historia natural de la enfermedad. Estudio y seguimiento de la "cohorte de pacientes de Esclerosis Múltiple de Vizcaya".
Investigación clínica farmacológica.
Investigación clínica sobre la evolución natural de la enfermedad en determinadas circunstancias (EM y embarazo, EM en pacientes pediátricos, EM y circunstancias relacionadas con el género, EM y co-morbilidad).
Investigación clínica e integración asistencial con atención primaria mediante el "protocolo Bilbao".
Estrategia conjunta de cooperación-comunicación entre distintos niveles asistenciales, en este caso, neurología y atención primaria para mejorar la eficiencia y la calidad asistencial.
Investigación sobre la comorbilidad de esta patología crónica.

 

Actividades del grupo:

El Servicio de Neurología del Hospital Universitario Cruces, cuenta con una larga tradición en investigación científica y en la atención clínica de máxima calidad de pacientes con Esclerosis Múltiple (EM), que se remonta a 1987 cuando se creó la primera consulta específica de dicha enfermedad de la red de hospitales de Osakidetza.

Los dos objetivos de esta unidad son el asistencial y científico que conviven en estrecha simbiosis y de ellos se nutre nuestra labor investigadora. Durante estos 24 años y de manera ininterrumpida, en el Hospital Universitario Cruces se han llevado a cabo múltiples proyectos de investigación científica sobre la EM.

 

Estos proyectos pueden clasificarse en:

1) la investigación sobre la historia natural de la enfermedad, piedra angular sobre la que se sustentan todos nuestros trabajos científicos. Se lleva a cabo mediante  el estudio y seguimiento de la "cohorte de pacientes de Esclerosis Múltiple de Vizcaya"; una serie poblacional, dinámica, seguida prospectivamente desde hace 24 años.

2) investigación clínica farmacológica mediante la participación en ensayos clínicos internaciones con fármacos en fase II Y III. La mayoría de estos proyectos gestionados por BIOEF.

3) investigación clínica sobre la evolución natural de la enfermedad en determinadas circunstancias (EM y embarazo, EM en pacientes pediátricos, EM y circunstancias relacionadas con el género, EM y co-morbilidad).

4) investigación clínica e integración asistencial con atención primaria mediante el "protocolo Bilbao". Estrategia conjunta de cooperación-comunicación entre distintos niveles asistenciales, en este caso, neurología y atención primaria para mejorar la eficiencia y la calidad asistencial. Así como investigar sobre la comorbilidad de esta patología crónica.

En estos proyectos colaboramos estrechamente con nuestro homónimo del Hospital de Basurto, lo cual incrementa nuestro valor como equipo interhospitalario y nos permite investigar conjuntamente sobre "LaCohortede pacientes de EM de Vizcaya".

Colaboramos con el departamento de neurociencias de la UPV, en concreto con los equipos del Profesor Carlos Matute y del Dr. K. Vandenbroeck.

Coordinador/a del grupo



Miembros del grupo

  Mar Mendibe Bilbao
 
 
  Susana Mato Santos
 
  Ana Bernal Chico
 
  Jose Eulalio Barcena Llona
 
 
  Sabas Boyero Duran
 
 
  Andrés Mateo Baraibar Sierra
 
  Álvaro Moreno García
 
  Teresa Colomer Molla
 
  Fabrizio Livrone
 
  Maialen Martínez Preciado
 
 
  Ana Moreno Estébanez
 
 

Publicaciones del grupo

Bernal Chico A, Tepavcevic V, Manterola A, Utrilla C, Matute C, Mato S. Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells. Glia. 2022. DOI:10.1002/glia.24172.

Brieva L, Estruch BC, Merino JAG, Meca Lallana V, Rio J, Rodriguez Antiguedad A, et al. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Mult Scler Relat Disord. 2022; 63: 103805-103805. DOI:10.1016/j.msard.2022.103805.

Garcia M, Rouco Axpe I, Amayra I, Rodriguez Antiguedad A, Catalli C, Cabrera Zubizarreta A, et al. Neuropsychological Profile of Hereditary Ataxias: Study of 38 Patients. Arch Clin Neuropsychol. 2022; 37(5): 904-915. DOI:10.1093/arclin/acac024.

Martin Prieto J, Rouco Axpe I, Moreno Estebanez A, Rodriguez Antiguedad Zarrantz A. Rapid cognitive decline associated with anti-glutamic acid decarboxylase antibodies: a case report. Neurologia (Engl Ed). 2022; 37(2): 151-152. DOI:10.1016/j.nrleng.2021.04.005.

Lopez Soley E, Meca Lallana JE, Llufriu S, Blanco Y, Gomez Ballesteros R, Maurino J, et al. Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. J Pers Med. 2022; 12(5). DOI:10.3390/jpm12050743.

Meca Lallana JE, Gomez Ballesteros R, Perez Miralles F, Forero L, Sepulveda M, Calles C, et al. Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study. Neurol Ther. 2022. DOI:10.1007/s40120-022-00356-6.

Saposnik G, Bueno Gil G, Sempere AP, Del Rio Munoz B, Lendinez Mesa A, Azanza Munarriz C, et al. Sick leave and occupational burnout among nurses caring for patients with multiple sclerosis. Mult Scler Relat Disord. 2022; 63: 103916-103916. DOI:10.1016/j.msard.2022.103916.

Ruiz Lopez M, Estebanez M, Tijero B, Fernandez T, Rebollo Perez A, Gabilondo I, et al. Pearls and Oy-sters: Challenges and Controversies in Wilson Disease. Neurology. 2022; 99(6): 251-255. DOI:10.1212/WNL.0000000000200836.

Sanchez de la Torre A, Aguado T, Huerga Gomez A, Santamaria S, Gentile A, Carlos Chara J, et al. Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice. Cell Death Dis. 2022; 13(7). DOI:10.1038/s41419-022-05032-z.

Alonso Torres A, Arevalo Bernabe A, Becerril Rios N, Hellin Gil M, Martinez Sesmero J, Meca Lallana V, et al. Cost-analysis of subcutaneous versus intravenous administration for natalizumab in Multiple Sclerosis in Spain. Eur J Neurol. 2022; 29: 630-631

Meca Lallana JE, Casanova B, Rodriguez Antiguedad A, Eichau S, Izquierdo G, Duran C, et al. Consensus on early detection of disease progression in patients with multiple sclerosis. Front Neurol. 2022; 13: 931014-931014. DOI:10.3389/fneur.2022.931014.

Ramos Gonzalez P, Mato S, Chara JC, Verkhratsky A, Matute C, Cavaliere F. Astrocytic atrophy as a pathological feature of Parkinson's disease with LRRK2 mutation. npj Parkinsons Dis. 2021; 7(1). DOI:10.1038/s41531-021-00175-w.

Martin Prieto J, Rouco Axpe I, Moreno Estebanez A, Rodriguez Antiguedad Zarrantz A. Rapid cognitive decline associated with anti-glutamic acid decarboxylase antibodies: A case repot. Neurologia (Engl Ed). 2021. DOI:10.1016/j.nrl.2021.04.005.

Fernandez O, Montalban X, Aladro Y, Alonso A, Arroyo R, Calles C et al. 13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (I). Rev Neurologia. 2021; 72(11): 397-406. DOI:10.33588/rn.7211.2021172.

Meca Lallana JE, Prefasi D, Perez Miralles F, Forero L, Sepulveda M, Calles C et al. Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder. Patient Prefer Adherence. 2021; 15: 713-719. DOI:10.2147/PPA.S305707.

Meca Lallana J, Garcia Merino JA, Martinez Yelamos S, Vidal Jordana A, Costa L, Eichau S et al. Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies. Neurodegener Dis Manag. 2021; 11(03): 251-261. DOI:10.2217/nmt-2020-0049.

Sifontes Valladares W, Moreno Estebanez A, Diaz Cuervo I, Martin Prieto J, Agirre Beitia G, Cabral Martinez L et al. Autoimmune encephalitis with antibodies against LGI1: broadening the spectrum of dystonic seizures. Eur J Neurol. 2021; 28: 393-393.

Martin Prieto J, Rouco Axpe I, Moreno Estebanez A, Velasco Palacios L, Boyero S, Mendibe Bilbao M et al. Rapid cognitive decline associated with anti-glutamic acid decarboxylase autoantibodies (GAD): a case report. Eur J Neurol. 2021; 28: 562-562.

Fernandez O, Montalban X, Aladro Y, Alonso A, Arroyo R, Calles C et al. 13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (II). Rev Neurologia. 2021; 72(12): 433-442. DOI:10.33588/rn.7212.2021173.

Saposnik G, Bueno Gil G, Sempere AP, Rodriguez Antiguedad A, del Rio B, Baz M et al. Regret and Therapeutic Decisions in Multiple Sclerosis Care: Literature Review and Research Protocol. Front Neurol. 2021; 12. DOI:10.3389/fneur.2021.675520.

Meca Lallana JE, Maurino J, Perez Miralles F, Forero L, Sepulveda M, Calles C et al. Quantifying the patients perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire. PLoS One. 2021; 16(7): 255317-255317. DOI:10.1371/journal.pone.0255317.

Aguado T, Huerga Gomez A, Sanchez de La Torre A, Resel E, Chara JC, Matute C et al. Delta(9)-Tetrahydrocannabinol promotes functional remyelination in the mouse brain. Br J Pharmacol. 2021; 178(20): 4176-4192. DOI:10.1111/bph.15608.

Echeazarra L, del Cano GG, Barrondo S, Gonzalez Burguera I, Saumell Esnaola M, Aretxabala X et al. Fit-for-purpose based testing and validation of antibodies to amino- and carboxy-terminal domains of cannabinoid receptor 1. Histochem Cell Biol. 2021; 156(5): 479-502. DOI:10.1007/s00418-021-02025-5.

Meca Lallana JE, Oreja Guevara C, Muñoz D, Olascoaga J, Pato A, Ramió Torrentà L et al. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. PLoS One. 2021; 16(10). DOI:10.1371/journal.pone.0258437.

Gomez Carballo C, Moreno Estebanez A, Diaz Cuervo I, Fernandez Rodriguez V, Jauregi Barrutia A. Coexistence of antiCASPR2 autoimmune encephalitis, normotensive hydrocephalus and Alzheimer's disease: when Ockham's razor faces clinical practice. Neurol Sci. 2021; 42(11): 4829-4831. DOI:10.1007/s10072-021-05554-y.

Bayon Cordero L, Ochoa Bueno BI, Serrano Regal MP, Tepavcevic V, Capetillo Zarate E, Zallo F et al. GABA(B) receptor downstream mechanisms in OPCs and its role in myelination and remyelination. Glia. 2021; 69: 540-541.

Meca Lallana J, Gomez Ballesteros R, Perez Miralles F, Forero L, Sepulveda M, Calles C et al. Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective. J Neurol Sci. 2021; 429: 31-31. DOI:10.1016/j.jns.2021.118844.

Ayuso GI, Guevara CO, Rodriguez EA, Quilez MRB, Lallana VM, Lallana J et al. Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis. Mult Scler J. 2021; 27(2_SUPPL): 274-275.

Mena J, Alloza I, Tulloch Navarro R, Aldekoa A, Díez García J, Villanueva Etxebarria A et al. Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55-IL6ST Gene Region in Immature Dendritic Cells. Front Immunol. 2021; 12: 816930-816930. DOI:10.3389/fimmu.2021.816930.

Oreja Guevara C, Rio J, Callizo J, Perez M, Gil JG, Torres A et al. Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study. Mult Scler J. 2021; 27(2_SUPPL): 306-307.

Meca Lallana V, Rodriguez Antiguedad A, Llaneza MA, Meca Lallana JE. Plasma determination of neurofilaments as biomarkers in multiple sclerosis: conclusions of the EMotion Forum. Rev Neurologia. 2021; 73(3): 101-110. DOI:10.33588/rn.7303.2020691.

Lallana JM, Prefasi D, Casanova B, Diaz LF, Saiz A, Calles C et al. Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study). Neurology. 2021; 96(15).

Saposnik G, Del Rio B, Bueno Gil G, Sempere AP, Lendinez Mesa A, Rodriguez Antiguedad A et al. Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain. PLoS One. 2021; 16(12). DOI:10.1371/journal.pone.0261050.

Oreja C,Rio J,Ara JR,Hernandez MA,Gracia J,Ramio I Torrenta L,Pilo De La Fuente B,Alonso AM,Martinez S,Gascon F,Eichau S,Casanova B,Martinez ML,Aguado ML,Martinez JE,Lopez AM,Lopez De Silanes C,Gonzalez V,El Berdei Y,Labiano A,Garces M,Costa L,Garcia JA,Castellanos F,Munoz C,Meca V,Castillo T,Rodriguez A,Pena J,Prieto JM,Solar DM,Perez I,Aguera E,Herrera N,Meca J. Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study. Mult. Scler. J. 2020. 26. (3_SUPPL):p. 603-604. IF:6,312. (1).

Oreja C,Casanova B,Garcia JA,Costa L,Fernandez D,Ara JR,Prieto J,Calles C,Hernandez MA,Rio J,Duran C,Izquierdo G,Eichau S,Rodriguez A,Moreno MJ,Fernandez D,Meca J. Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients. Mult. Scler. J. 2020. 26. (3_SUPPL):p. 240-241. IF:6,312. (1).

Calovi S,Mut P,Tod P,Iring A,Nicke A,Mato S,Vizi ES,Tonnesen J,Sperlagh B. P2X7 Receptor-Dependent Layer-Specific Changes in Neuron-Microglia Reactivity in the Prefrontal Cortex of a Phencyclidine Induced Mouse Model of Schizophrenia. Front. Molec. Neurosci. 2020. 13. 566251. IF:5,639. (1).

Agirre G,Moreno A,Gonzalez TGP,Jimenez BM,Rodriguez IC,Martinez LC,Barrutia AJ,Eizaguirre AG,Romero IC,Llona JB,Gomez JC. FOSMN A possible TDP-43 proteinopathy to consider in a patient with facial sensory symptoms. Neurol.-Clin. Pract. 2020. 10. (5):p. 47-50. .

Huerga A,Aguado T,Sanchez A,Bernal A,Matute C,Mato S,Guzman M,Galve I,Palazuelos J. Delta9 -Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo. Glia. 2020. 69. (3):p. 532-545. IF:7,452. (1).

Habbane M,Llobet L,Bayona MP,Barcena JE,Ceberio L,Gomez C,Gort L,Artuch R,Montoya J,Ruiz E. Leigh Syndrome in a Pedigree Harboring the m.1555A>G Mutation in the Mitochondrial 12S rRNA. Genes. 2020. 11. (9):IF:4,096. (2).

Moreno A,Bernal A,Colomer T,Rodriguez A,Matute C,Mato S. Gene Expression Analysis of Astrocyte and Microglia Endocannabinoid Signaling during Autoimmune Demyelination. Biomolecules. 2020. 10. (9):1228. IF:4,879. (2).

Otero S,Rodriguez J,Vilella A,Ara JR,Brieva L,Calles C,Carmona O,Casanova V,Costa L,Eichau S,Garcia JA,Garcia C,Gonzalez M,Llaneza M,Martinez M,Meca JE,Prieto JM,Rodriguez A,Tintore M,Blanco Y,Moral E,en nombre S. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. Neurologia. 2020. 36. (1):p. 50-60. IF:3,109. (3).

Berriozabalgoitia R,Sanz B,Fraile AB,Otxoa E,Yeregui I,Bidaurrazaga I,Dunabeitia I,Antiguedad A,Domercq M,Irazusta J,Rodriguez A. An Overground Robotic Gait Training Program for People With Multiple Sclerosis: A Protocol for a Randomized Clinical Trial. Front. Med. 2020. 7. 238. IF:5,091. (1).

Fernandez O,Aladro Y,Arroyo R,Brieva LL,Calles MC,Carrascal P,Comabella M,Costa L,Eichau S,Garcia JA,Ginestal R,Gonzalez I,Izquierdo G,Martinez ML,Meca JE,Mendibe MM,Oterino A,Prieto JM,Rio J,Ramio LL,Romero L,Tellez N,Rodriguez A. 12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (II). Rev. Neurologia. 2020. 70. (11):p. 417-429. IF:0,870. (4).

Fernandez O,Aladro Y,Arroyo R,Brieva LL,Calles MC,Carrascal P,Comabella M,Costa L,Eichau S,Garcia JA,Ginestal R,Gonzalez I,Izquierdo G,Martinez ML,Meca JE,Mendibe MM,Oterino A,Prieto JM,Rio J,Ramio LL,Romero L,Tellez N,Rodriguez A. [12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (I)]. Rev. Neurologia. 2020. 70. (10):p. 379-390. IF:0,870. (4).

Garamendi I,Martinez MJ,Galbarriatu L,Marinas A,Pomposo I,Santos C,Gomez JC,Garcia A,Sanchez M,Perez T,Altamirano J,Zarrantz AR. 20-year experience with Vagus Nerve Stimulation Therapy for drug-resistant epilepsy in a single centre. Eur. J. Neurol. 2020. 27. p. 152-152. IF:6,089. (1).
Gonzalez T,Luna A,Moreno A,Agirre G,Rodriguez A,Ruiz M. Emergency Room Neurology in times of COVID-19: Malignant Ischemic Stroke and SARS-COV2 Infection. Eur. J. Neurol. 2020. 27. (9):p. 35-36. IF:6,089. (1).

Matias J,Matias JA,Alvarez J,Ara JR,Arenillas J,Casado I,Castellanos M,Jimenez MD,Lainez JM,Moral E,Morales A,Rodriguez A,Segura T,Serrano P,Diez E. Will neurological care change over the next 5 years due to the COVID-19 pandemic?. Neurologia. 2020. 35. (4):p. 252-257. IF:3,109. (3).

Moreno A,Losada JM,Gonzalez T,Rodriguez A. Isolated pseudotumoural demyelination: A focal, monophasic autoimmune encephalitis?. Neurologia. 2020. 35. (3):p. 217-219. IF:3,109. (3).

Armangue T,Olivé G,Martínez E,Sepulveda M,Ruiz R,Muñoz M,Ariño H,González V,Felipe A,Jesús Martínez M,Cantarín V,Concepción Miranda M,Monge L,Tomás M,Miravet E,Málaga I,Arrambide G,Auger C,Tintoré M,Montalban X,Vanderver A,Graus F,Saiz A,Dalmau J,Spanish Pediatric anti G,Alcantud A,Aguilera S,Alvarez D,Alvarez M,Aquino L,Arrabal L,Arriola G,Aznar G,Benavides M,Bermejo T,Blanco R,Caballero E,Calvo R,Camacho A,Conejo D,Delgadillo V,Elosegi A,Esteban V,Fernández J,Garcia M,García A,Gómez H,Gonzalez D,González L,Jimena S,Jiménez M,Juliá N,López E,Martí I,Martínez M,Martín L,Mattozi S,Maqueda E,Mendibe MDM,Mora MD,Muñoz B,Navarro J,Nunes T,Orellana G,Pujol B,Querol L,Ramírez A,Rodriguez MI,Ruiz C,Soto V,Toledo Bravo de Laguna L,Turon E,Vázquez M,Villar C. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020. 19. (3):p. 234-246. IF:44,182. (1).

Moreno A,Bilbao I,Echeverria T,Mendibe M,Boyero S,Cabral L,González T,Agirre G,González A,Rodríguez A. Positive oligoclonal bands and CSF pleocytosis in narcolepsy type 1: A case report supporting the immune-mediated hypothesis. J Neuroimmunol. 2020. 339. p. 577111-577111. IF:3,478. (3).

Meca JE,Fernández M,García E,Moreno S,Otero S,Rus M,Villar LM,Eichau S,Fernández Ó,Izquierdo G,Álvarez JC,Arnal C,Arroyo R,Brieva L,Calles C,García A,González M,Hernández MÁ,Moral E,Olascoaga J,Oliva P,Oreja C,Ortiz R,Oterino A,Prieto JM,Ramió L,Rodríguez A,Saiz A,Tintoré M,Montalbán X. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. Neurologia. 2020. IF:3,109. (3).

Miñón B,Losada JM,Sánchez MT,Bárcena J. Miastenia grave asociada a nivolumab. Rev. Neurologia. 2020. 70(2):p. 72-73. IF:0,870. (4).

Mendibe Bilbao M, Boyero Durán S, Bárcena Llona J, Rodriguez-Antigüedad A. Multiple sclerosis: Pregnancy and women's health issues.. Neurologia. 2019; 34(4): 259 - 269. FI: 2,038(Q3). DOI: 10.1016/j.nrl.2016.06.005.

Fernandez, Oscar, Tintore, Mar, Saiz, Albert, Carmen Calles-Hernandez, M., Comabella, Manuel, Ramio-Torrenta, Lluis, Oterino, Agustin, Izguierdo, Guillermo, Tellez, Nieves, Garcia Merino, Juan A., Brieva, Lluis, Arnal-Garcia, Carmen, Aladro, Yolanda, del Mar Mendibe-Bilbao, Maria, Meca-Lallana, Jose E., Romero-Pinel, Lucia, Luisa Martinez-Gines, M., Arroyo, Rafael, Oreja-Guevara, Celia, Costa-Frossard, Lucienne, Carrascal, Pedro, Rodriguez-Antiguedad, Alfredo. Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (I). Rev. Neurologia. 2019; 68(10): 431 - 441. FI: 0,485(Q4). DOI: 10.33588/rn.6810.2019120.

Fernandez, Oscar, Tintore, Mar, Saiz, Albert, Carmen Calles-Hernandez, M., Comabella, Manuel, Ramio-Torrenta, Lluis, Oterino, Agustin, Izquierdo, Guillermo, Tellez, Nieves, Garcia Merino, Juan A., Brieva, Lluis, Arnal-Garcia, Carmen, Aladro, Yolanda, del Mar Mendibe-Bilbao, Maria, Meca-Lallana, Jose E., Romero-Pinel, Lucia, Luisa Martinez-Gines, M., Arroyo, Rafael, Oreja-Guevara, Celia, Costa-Frossard, Lucienne, Carrascal, Pedro, Rodriguez-Antiguedad, Alfredo. Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (II). Rev. Neurologia. 2019; 68(11): 468 - 479. FI: 0,485(Q4). DOI: 10.33588/rn.6811.2019121.

Vilarino-Guell, Carles, Zimprich, Alexander, Martinelli-Boneschi, Filippo, Herculano, Bruno, Wang, Zhe, Matesanz, Fuencisla, Urcelay, Elena, Vandenbroeck, Koen, Leyva, Laura, Gris, Denis, Massaad, Charbel, Quandt, Jacqueline A., Traboulsee, Anthony L., Encarnacion, Mary, Bernales, Cecily Q., Follett, Jordan, Yee, Irene M., Criscuoli, Maria G., Deutschlander, Angela, Reinthaler, Eva M., Zrzavy, Tobias, Mascia, Elisabetta, Zauli, Andrea, Esposito, Federica, Alcina, Antonio, Izquierdo, Guillermo, Espino-Paisan, Laura, Mena, Jorge, Antiguedad, Alfredo, Urbaneja-Romero, Patricia, Ortega-Pinazo, Jesus, Song, Weihong, Sadovnick, A. Dessa. Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease. PLoS Genet. 2019; 15(6): e1008180. FI: 5,224(Q1). DOI: 10.1371/journal.pgen.1008180.

Garamendi, I., Garcia Martinez, A., Matute Nieves, A., Garcia Rua, A., Marinas Alejo, A., Suarez Santos, P., Martinez Gonzalez, M. J., Castanon Apilanez, M., Gomez Esteban, J. C., Ameijide, E., Rodriguez-Antiguedad Zarrantz, A.. One-year clinical experience with brivaracetam in spain: Study of the efficacy and tolerability. Eur. J. Neurol.. 2019; 26: 131 - 131. FI: 4,387(Q1). DOI: .

Fernadez-Fernandez, O., Rodriguez-Antiguedad, A., Aboin Sierra, J.. Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: real-world results - interim results of second year follow-up. Mult. Scler. J.. 2019; 25: 764 - 765. FI: 5,649(Q1). DOI: .

Rio, J., Brieva, L., Costa-Frossard, L., Garcia Dominguez, J. M., Oreja-Guevara, C., Pena, J., Rodriguez-Antiguedad, A., Moreno, M. J., Arroyo, R., Spanish Panel Experts. Assessment and follow-up of the response to disease modifying treatments in multiple sclerosis: Spanish expert consensus. Mult. Scler. J.. 2019; 25: 784 - 785. FI: 5,649(Q1). DOI: .

Oreja-Guevara, Celia, Garcia-Merino, Juan A., Saiz, Albert, Rodriguez-Antiguedad, Alfredo, Alvarez-Cermeno, Jose C., Estrada-Perez, Vicente, Izquierdo, Guillermo, Fernandez, Oscar. Recommendations for the use of cladribine tablets in recurring multiple sclerosis. Rev. Neurologia. 2019; 69(2): 1 - 9. FI: 0,485(Q4). DOI: .

Oreja-Guevara C, García-Merino JA, Saiz A, Rodríguez-Antigüedad A, Álvarez-Cermeño JC, Estrada-Pérez V, Izquierdo G, Fernández O. Recomendaciones de uso de cladribina comprimidos en la esclerosis múltiple recurrente.. Rev. Neurologia. 2019; 69(s02): 1 - 9. FI: 0,485(Q4). DOI: 10.33588/rn.69s02.2019380.

 

Alerany C, Fernandez R, Landete L, Rodriguez A, Sandoval S, Valdivia M, et al. Determining the value of ocrevus (r) (ocrelizumab) for the treatment of multiple sclerosis in spain by multi-criteria decision analysis (MCDA). Value Health. 2018; 21(3): 345 - 345. MEETING ABSTRACT.

Rilo O, Peña J, Ojeda N, Rodríguez-Antigüedad A, Mendibe-Bilbao M, Gómez-Gastiasoro A, et al. Integrative group-based cognitive rehabilitation efficacy in multiple sclerosis: a randomized clinical trial. Disabil. Rehabil. 2018; 40(2): 208 - 216. FI: 2,042(Q1). DOI: 10.1080/09638288.2016.1250168.

Fernandez O, Tintore M, Saiz A, Calles-Hernandez MC, Comabella M, Ramio-Torrenta L, et al. Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post- ECTRIMS Meeting (II). Rev Neurol. 2018; 67(2): 50 - 62. FI: 0,601(Q4). DOI: 10.33588/rn.6702.2018193. REVIEW-

Fernandez O, Tintore M, Saiz A, Calles-Hernandez MC, Comabella M, Ramio-Torrenta L, et al. Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post-ECTRIMS Meeting (I). Rev Neurol. 2018; 67(1): 15 - 27. FI: 0,601(Q4). DOI: 10.33588/rn.6701.2018192. REVIEW.

Fernandez O, Rodriguez-Antiguedad A, Cadima R, Botella I. Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: real-world results and initial results of first year follow-up. Mult. Scler. J. 2018; 24(2): 930 - 930. MEETING ABSTRACT.

Cortes-Vicente E, Rojas-Garcia R, Diaz-Manera J, Querol L, Casasnovas C, Guerrero-Sola A, et al. The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann. Clin. Transl. Neurol. 2018; 5(6): 710 - 716. FI: 4,649(Q1). DOI: 10.1002/acn3.564.

 

Caro SV, Antiguedad AR, Bilbao MM, Caro PV. NeuronUp as a tool for Cognitive Rehabilitation in MS. Mult Scler. 2017;23:882. FI:4,840(Q1). ABSTRACT

Cipriani R, Chara JC, Rodriguez-Antiguedad A, Matute C. Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury. J Neuroinflamm. 2017;14:141 . FI:5,102(Q1). DOI:10.1186/s12974-017-0922-6.

Fernandez O, Oterino A, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MD, Garcia-Merino JA, et al. Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I). Rev Neurologia. 2017;65:31-40. FI:0,743(Q4).

Fernandez O, Oterino A, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MD, Garcia-Merino JA, et al. Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II). Rev Neurologia. 2017;65:75-84. FI:0,743(Q4).

Gabilondo I, Rilo O, Ojeda N, Pena J, Gómez-Gastiasoro A, Mendibe Bilbao M, et al. The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis. Mult Scler. 2017;23:1276-88. FI:4,840(Q1). DOI:10.1177/1352458516676642.

Rilo O, Ojeda N, Pena J, Cabrera A, Rodriguez-Antiguedad A, Mendibe-Bilbao M, et al. Maintenance of the default mode network functional connectivity through; an integrative group-based cognitive rehabilitation in multiple sclerosis. Mult Scler. 2017;23:891. FI:4,840(Q1). ABSTRACT

Rilo O, Pena J, Gomez-Gastiasoro A, Ibarretxe-Bilbao N, Del Pino R, Rodriguez-Antiguedad A, et al. Estimation of verbal memory and processing speed cognitive performance according to premorbid intelligence in multiple sclerosis patients Running tittle: Estimation of cognitive performance in MS. Mult Scler. 2017;23:905. FI:4,840(Q1). ABSTRACT

 

Fernandez O, Rodriguez-Antiguedad A, Olascoaga J, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, et al. Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. Rev Neurol. 2016;62:559-69. FI:0,684(Q4).

Meca-Lallana J, Mendibe M, Hernandez-Clares R, Caminero AB, Mallada-Frechin J, Davila-Gonzalez P, et al. Predictors of burden and depression among caregivers of relapsing-remitting MS patients in Spain: MS Feeling study. Neurodegener Dis Manag. 2016;6:277-87. DOI:10.2217/nmt-2016-0014.

Mendibe Bilbao M, Boyero Durán S, Bárcena Llona J, Rodriguez-Antigüedad A. Multiple sclerosis: Pregnancy and women's health issues. Neurologia. 2016;pii:S0213-4853(16)30101-3. DOI:10.1016/j.nrl.2016.06.005. [Epub ahead of print]

Rilo O, Peña J, Ojeda N, Rodríguez-Antigüedad A, Mendibe-Bilbao M, Gómez-Gastiasoro A, et al. Integrative group-based cognitive rehabilitation efficacy in multiple sclerosis: a randomized clinical trial. Disabil Rehabil. 2016;1-9. DOI:10.1080/09638288.2016.1250168. [Epub ahead of print]

Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, et al. Neuromyelitis optica spectrum disorders Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflammation. 2016;3:e225. DOI:10.1212/NXI.0000000000000225.

 

Agundez M, Rouco I, Barcena J, Mateos B, Barredo J, Zarranz JJ. Hirayama disease: Is surgery an option?. Neurologia. 2015;30:502-509. FI:1,790(Q4). DOI:10.1016/j.nrl.2013.05.005.

Gabilondo I, Rilo O, Ojeda N, Pena J, Gomez A, Mendibe M, et al. Visual information processing speed and the damage to posterior visual pathway in multiple sclerosis. Mult Scler J. 2015;21:50-0. FI:4,671(Q1). ABSTRACT

Meca-Lallana J, Mendibe M, Hernandez-Clares R, Caminero AB, Mallada J, Davila P, et al. Burden and depression in caregivers and patients with multiple sclerosis. MS-feeling study. Mult Scler J. 2015;21:338. FI:4,671(Q1). ABSTRACT

Mendibe M, Boyero S, Llarena C, Rodriguez-Antiguedad A. Demographic and clinical profile of PEDIATRIC patients with multiple sclerosis: descriptive analysis of a prospective monitored, population-based cohort study in the Basque Country (Spain). Mult Scler J. 2015;21:97. FI:4,671(Q1). ABSTRACT

Querol LA, Rojas-Garcia R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, et al. Rituximab is effective in treatment-resistant CIDP with IgG4 antibodies against paranodal proteins. Eur J Neurol. 2015;22:39. FI:3,956(Q1). ABSTRACT

Querol LA, Rojas-Garcia R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, et al. Rituximab is effective in treatment-resistant cidp with IGG4 antibodies against paranodal proteins. J Peripher Nerv Syst. 2015;20:214-215. FI:2,258(Q3). ABSTRACT

Rilo O, Pena J, Ojeda N, Gomez A, Mendibe M, Rodriguez A, et al. The role of processing speed in multiple sclerosis cognitive impairment. Mult Scler J. 2015;21:520-521. FI:4,671(Q1). ABSTRACT

Rilo O, Pena J, Ojeda N, Rodriguez A, Mendibe M, Gomez A, et al. Integrative group-based cognitive rehabilitation efficacy in multiple sclerosis. Mult Scler J. 2015;21:230-231. FI:4,671(Q1). ABSTRACT

 

Fernández Ó, Álvarez-Cermeño JC, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, et al; Grupo Post-ECTRIMS. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III). Rev Neurol. 2014;59:371-9. FI: 0,830(Q4)

Fernández Ó, Álvarez-Cermeño JC, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, et al; Grupo Post-ECTRIMS. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurol. 2014;59:307-16. FI: 0,830(Q4)

Fernández Ó, Álvarez-Cermeño JC, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, et al; Grupo Post-ECTRIMS. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Rev Neurol. 2014;59:269-80. FI: 0,830(Q4)

Rodríguez-Antigüedad Zarranz A, Mendibe Bilbao M, Llarena González C, Audicana C. Mortality and Cause of Death in Multiple Sclerosis: Findings from a Prospective Population-Based Cohort in Bizkaia, Basque Country, Spain. Neuroepidemiology. 2014;42:219-25. FI: 2,558(Q2)

Balana M, Fabregas M, Meca-Lallana J, Mendibe M, Garcia E. Factors associated with caregiver's burden in relapsing-remitting multiple sclerosis and satisfaction with current therapies. MS-feeling study. Value Health. 2014;17:402. FI: 3,279(Q1)

Meca-Lallana J, Mendibe M. Stress burden and satisfaction with treatment in caregivers and patients with multiple sclerosis. MS-feeling study. Mult Scler J. 2014;20:392. FI: 4,822(Q1)

 

Höftberger R, Titulaer MJ, Sabater L, Dome B, Rózsás A, Hegedus B, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81:1500-6. FI: 8,249(Q1)

Fernández Ó, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, et al; Post-ECTRIMS Group. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III). Rev Neurologia. 2013;57:317-29. FI: 1,179(Q4)

Antigueedad A, Llarena C, Mendibe M. Mortality and cause of death in multiple sclerosis: findings from a prospective population-based cohort in Bizkaia, Spain. Mult  Scler J. 2013;19:97. FI: 4,472(Q1)

Fernández Ó, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, et al; Post-ECTRIMS Group. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurologia. 2013;57:269-81. FI: 1,179(Q4)

Fernández Ó, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, et al; Post-ECTRIMS Group. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Rev Neurologia. 2013;57:217-29. FI: 1,179(Q4)

Agundez M, Rouco I, Barcena J, Mateos B, Barredo J, Zarranz JJ. Hirayama disease: Is surgery an option?. Neurologia 2013; -0. FI: 1,322(Q3)

Sepúlveda M, Blanco Y, Rovira A, Rio J, Mendibe M, Llufriu S, et al. Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Mult Scler  J. 2013;19:742-8. FI: 4,472(Q1)

 

Tesis del grupo

Autor/a: Andrea Manterola Juaristi. Título: "Therapeutic potencial of the endocannabinoid system in multiple sclerosis: novel clues from oligodendrocyte CB1 receptors and ABHD6/Endokannabinoide sistemaren potentzial terapeutikoa esklerosi anizkoitzean: Oligodendrozitoetako CB1 hartzaileen eta ABHD". Directores/as: Dr. Carlos Matute Almao, Dra. Susana Mato Santos.

© 2022 IIS Biocruces Bizkaia